Find the best no-KYC crypto exchanges for 2026. Compare top anonymous swap platforms with no registration. Trade crypto ...

ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA ...

The Last Check, the Lazarus Bulletin Board task is one of the first bonus objectives players encounter. The task requires ...

The NEO-CYT study, sponsored by Fondazione Melanoma Onlus, will be evaluating MDNA11 in front-line therapy for resectable ...

If you fall into the latter category and like to formulate your own plans in open-world games, then I have a few ...

"What is the cost to the people?" asked a resident who said he'd not been informed of numerous chemicals lacing a plot he'd ...

AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, compared to ...

KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected ...

Dual anti-platelet therapy remains a cornerstone of the treatment for coronary artery disease. When choosing a second ...

Compare the best online casinos in Israel for real-money play. Updated %%currentyear%% guide with bonuses, games, and safe ...

ORR was 50% in patients treated with MDNA11 in 2L/3L setting and 42% when MDNA11 was the next treatment post-ICI failure, ...

(Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today ...